Imiquimod Has Sustained Benefit for Basal Cell Carcinoma

Share this content:
Imiquimod Has Sustained Benefit for Basal Cell Carcinoma
Imiquimod Has Sustained Benefit for Basal Cell Carcinoma

FRIDAY, Dec. 16, 2016 (HealthDay News) -- For superficial or nodular basal cell carcinoma at low-risk sites, imiquimod has lower treatment success rates than surgery but the benefit is sustained at five years, according to a study published online Dec. 5 in the Journal of Investigative Dermatology.

Hywel C. Williams, Ph.D., from the University of Nottingham in the United Kingdom, and colleagues reported five-year data from a noninferiority randomized controlled SINS trial that compared topical imiquimod with surgery for superficial or nodular basal cell carcinoma at low-risk sites. Participants were randomized to once-daily 5 percent imiquimod cream or excisional surgery. Five-year success was defined as three-year success plus absence of recurrence. Five hundred one patients were randomized; 401 contributed to the primary outcome in the modified intention-to-treat analyses at year three, of whom 383 had data available at year five.

The researchers found that the five-year success rates were 82.5 percent for imiquimod compared with 97.7 percent for surgery (relative risk of imiquimod success, 0.84; P < 0.001). These were comparable to the success rates of 83.6 and 98.4 percent for imiquimod and surgery, respectively, at three years. For imiquimod, most treatment failures occurred in year one.

"Although surgery is clearly superior to imiquimod, this study shows sustained benefit for lesions that respond early to topical imiquimod," the authors write.

The study was funded by Cancer Research UK. Meda, previously 3M, donated 5 percent imiquimod cream free of charge.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




More in Home

FDA Approves First Generic Under-the-Tongue Suboxone

FDA Approves First Generic Under-the-Tongue Suboxone

May only be prescribed by Drug Addiction Treatment Act-certified prescribers

Kellogg's Honey Smacks Cereal Recalled Due to Salmonella Risk

Kellogg's Honey Smacks Cereal Recalled Due to <i>Salmonella</i> ...

Twenty-four people have been hospitalized, but no deaths have been reported

Portable Music Player Use Linked to Hearing Loss in Children

Portable Music Player Use Linked to Hearing Loss ...

Increased odds of high-frequency hearing loss with portable music player use

is free, fast, and customized just for you!




Already a member?

Sign In Now »